Transdermal clonidine for smoking cessation: A double-blind randomized dose–response study.

A 4-week trial tested the effects of 4 doses (placebo, 0.1 mg/d, 0.2 mg/d, and 0.3 mg/d) of transdermal clonidine on smoking cessation and nicotine withdrawal. After a 1-week baseline, smokers (N?=?72) started the drug and tried to quit by Week 3. Significantly fewer smokers who received a placebo were abstinent at 5 days after quitting as compared with smokers who received clonidine at any dose (19% vs 57%, respectively, p?=?.007). Blood clonidine concentration interacted with nicotine dependence (p?     

Electrochemical method for the detection of lipase activity

A novel electrochemical technique for the general assay of lipase activity is described. The method utilizes a solid-supported lipase substrate, which is formed by dripping and drying a small amount of an ethanol solution of 9-(5'-ferrocenylpentanoyloxy)nonyl disulfide (FPONDS) onto gold modified by a hexanethiol self-assembled monolayer. The redox ferrocene group of FPONDS generates the electrochemical signal, the intensity of which is proportional to the number of FPONDS molecules at the interface. Electrochemical and surface-enhanced infrared absorption spectroscopic data, as well as control experiments with an engineered, deactivated mutant enzyme, demonstrate that the wild-type lipase from Thermomyces lanuginosus is capable of cleaving the ester bonds of FPONDS molecules via an enzymatic hydrolysis mechanism, which includes the adsorption of the lipase onto the substrate surface. The hydrolysis liberates the ferrocene groups from the interface triggering a decay of the electrochemical redox signal. The rate of the electrochemical signal decrease is proportional to the lipase activity/concentration. These data suggest a general method for the direct measure of enzymatic activity of lipases.     

Attribution and alcohol-mediated aggression.

48 males participated in an aggression task after receiving either alcoholic or placebo beverages and after being told that they had received either a high or a low dose of alcohol. All Ss in the alcohol group actually received the same dose. Measures of aggression were the intensity and duration of shock given to a bogus partner in a RT-pain perception task and a score on a posttask attitude questionnaire. Blood alcohol readings were taken 3 times during the session, and a locus of control scale was administered before and after drinking. For Ss in the alcohol conditions, blood alcohol levels averaged .079% before the task and .085% afterwards. Alcohol resulted in higher aggression scores only on the questionnaire measure, and an interaction between drug and attribution was found for the measure of shock duration. Attribution alone resulted in greater aggression on the measure of shock intensity. Ss in groups where the attribution was discrepant with the drug condition were the most aggressive on the measures of shock intensity and duration. These Ss became more external, reflecting a high correlation between their aggression and a stimulus tone. Results suggest that a person's increased aggressiveness when intoxicated results from an interaction between alcohol and an altered responsivity to provoking stimuli. (37 ref) (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

FIB micro-milled sapphire for GaN maskless epitaxial lateral overgrowth: a systematic study on patterning geometry

Journal of Materials Science: Materials in Electronics - A systematic study of the GaN epitaxial lateral overgrowth (ELO) of the focused ion beam (FIB) patterned sapphire substrate is presented....     

Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion.

We report a reanalysis of data from a prior study describing the event history of quitting smoking aided by bupropion, using recurrent-event models to determine the effect of the drug on occurrence of lapses and recoveries from lapse (resumption of abstinence). Data were collected on 1,070 subjects across two similar double-blind randomized clinical trials of bupropion versus placebo and fitted with separate Cox regression models for lapse and recovery. Analyses were split using discrete time-varying covariates between the treatment (weeks 1-10) and follow-up phases (end of treatment to 12 months). Bupropion was associated with slower lapse during treatment for both sexes, and being female was associated with faster lapse across both phases. Drug did not affect time to recovery for males but was associated with faster recovery among females, allowing women to recover as quickly as men. High levels of nicotine dependence did not affect time to lapse but were associated with slower recovery from lapse across treatment and follow-up phases. During the treatment phase, higher levels of baseline depression symptoms had no effect on time to lapse but were associated with slower recovery from lapse. Results highlight the asymmetry in factors preventing lapse versus promoting recovery. Specifically, dependence, depression symptoms, and a sex x drug interaction were found to affect recovery but not lapse. Further research disentangling lapse and recovery events from summary abstinence measures is needed to help us develop interventions that take advantage of bupropion at its best and that compensate where it is weak.     

Bupropion and cognitive-behavioral treatment for depression in smoking cessation.

This study is a randomized, double-blind, placebo-controlled clinical trial examining the effects of an intensive cognitive-behavioral mood management treatment (CBTD) and of bupropion, both singularly and in combination, on smoking cessation in adult smokers. As an extension of our previous work, we planned to examine the synergistic effects of CBTD and bupropion on smoking cessation outcomes in general and among smokers with depression vulnerability factors. Participants were 524 smokers (47.5% female, M (age) = 44.27 years) who were randomized to one of four 12-week treatments: (a) standard, cognitive-behavioral smoking cessation treatment (ST) plus bupropion (BUP), (b) ST plus placebo (PLAC), (c) standard cessation treatment combined with cognitive-behavioral treatment for depression (CBTD) plus BUP, and (d) CBTD plus PLAC. Follow-up assessments were conducted 2, 6, and 12 months after treatment, and self-reported abstinence was verified biochemically. Consistent with previous studies, bupropion, in comparison with placebo, resulted in better smoking outcomes in both intensive group treatments. Adding CBTD to standard intensive group treatment did not result in improved smoking cessation outcomes. In addition, neither CBTD nor bupropion, either alone or in combination, was differentially effective for smokers with single-past-episode major depressive disorder (MDD), recurrent MDD, or elevated depressive symptoms. However, findings with regard to recurrent MDD and elevated depressive symptoms should be interpreted with caution given the low rate of recurrent MDD and the low level of depressive symptoms in our sample. An a priori test of treatment effects in smokers with these depression vulnerability factors is warranted in future clinical trials.     

Symptoms of depression and survival experience among three samples of smokers trying to quit.

Symptoms of depression have been associated with increased smoking prevalence and failure to quit smoking in several cross-sectional and population-based studies. Few studies, however, have prospectively examined the ability of current symptoms of depression to predict failure to quit smoking in treatment-motivated smokers. Pretreatment depressed mood was assessed by 3 different methods in 3 separate samples, 2 of which comprised smokers receiving combined pharmacological and behavioral treatments and a 3rd in which smokers received self-help materials only. In all studies, time in days from quit day until the 1st cigarette was ascertained to document survival. Survival analyses showed that in all 3 studies survival time was significantly and negatively related to measures of even very low levels of pretreatment depressed mood. Results were replicated across 3 independent samples and were robust and uniformly clear, indicating that low levels of depressive symptoms assessed at baseline predict time to 1st cigarette smoked after attempted quitting. (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

Nanocomposite films and coatings produced by interaction between graphite oxide and Congo red

Nanocomposite films and coatings were produced from the aqueous solutions containing different proportions of graphite oxide (GO) and Congo red by filtering through a polycarbonate membrane filter into alkaline media. They were examined by electron microscopy, Raman and FTIR spectroscopy, XRD, contact angle, and electrical conductivity measurements. It was established that the Congo red is able to interact through its amino groups with different functional groups of GO to form larger moieties composed of the nanoplatelets of GO. Raman spectroscopy revealed quinoid-like ring structure for dye adhering to the GO. In the case when the interaction occurs with the terminal functional groups located on the edges of the nanoplateletes of GO, larger crystallites in the nanocomposite are formed. The interaction between the Congo red and functional groups of GO situated in a basal plane leads to more compact structure of the nanocomposite. Pulsed laser treatment was used to reduce GO to graphene. Raman spectra of laser treated areas show positive effect of addition of the Congo red on the graphene yield in nanocomposite coatings after the laser treatment.     

A study of electropolymerization of N,N-dimethylaniline

Electrochemical oxidation and polymerization of N,N-dimethylaniline at a gold electrode have been studied in an acidic solution. Both potential cycling and electrolysis at a controlled potential yield a thin film of a polymer that shows electrochemical activity in acidic and pH-neutral solutions. Raman spectra of sulfate- and polystyrenesulfonate-doped polymer have been obtained and analyzed. Two possibilities for electropolymerization have been considered – a simple polymerization yielding a “true” poly(N,N-dimethylaniline), and polymerization accompanied by a partial demethylation yielding poly(N-methylaniline). Based on the results obtained, the first one has been considered as most likely.